Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

CRISPR Therapeutics’ gene-editing treatments are highly customized and shockingly expensive. The market is watching to see if the underlying science can be applied to treat many diseases. The company ...

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...

CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021. The first drug from CRISPR Therapeutics launched early last year, but annualized sales are still less than $60 million ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...